MTATP6P20

Across TCGA pan-cancer cohorts, MTATP6P20 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MTATP6P20’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MTATP6P20 RNA is repressed in tumor relative to normal tissue. In most cancer types MTATP6P20 is over-expressed in tumor, although a few such as BRCA and READ show the opposite, repressed pattern.

BRCA, READ, and LUAD are the cancer types where MTATP6P20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTATP6P20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	−0.044	.009	4	view →
READ	All	III,IV	−0.145	.028	2	view →
LUAD	All	III,IV	−0.073	.039	1	view →
LUSC	All	II,III,IV	−0.058	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MTATP6P20–BRCA

Open the BRCA breakdown →